

**SENATE**  
**STATE OF MINNESOTA**  
**NINETIETH SESSION**

**S.F. No. 613**

(SENATE AUTHORS: ABELER)

DATE  
02/06/2017

D-PG  
511

Introduction and first reading  
Referred to Health and Human Services Finance and Policy

OFFICIAL STATUS

1.1 A bill for an act  
1.2 relating to health; establishing a pilot project for genetic marker testing.  
1.3 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

1.4 Section 1. **GENETIC MARKER TESTING PILOT PROGRAM.**

1.5 Subdivision 1. **Establishment.** The commissioner of management and budget in  
1.6 collaboration with the commissioner of health shall establish a genetic marker testing pilot  
1.7 program. The commissioner of management and budget shall enlist volunteers from the  
1.8 state employees group insurance plan (SEGIP) to participate in the program. Minnesota  
1.9 Management and Budget shall oversee the administrative aspects of the program. The  
1.10 program is intended to refine the understanding of disease onset and progression, treatment  
1.11 response, and health outcomes through more precise measurement of genetic factors that  
1.12 contribute to health and disease.

1.13 Subd. 2. **Program design.** (a) Between 2,500 and 5,000 participants shall be selected  
1.14 from enrollees in the Blue Cross Blue Shield Advantage plan pool under SEGIP. One-third  
1.15 of the participants shall be randomly selected. The program shall be conducted over a  
1.16 four-year period. All participation in the program is voluntary.

1.17 (b) The commissioner of management and budget shall partner with Mayo Clinic Biobank  
1.18 to collect and store biospecimens from all program participants. Mayo Clinic Biobank shall  
1.19 utilize its established privacy, security, and systems protocols and protections for this pilot  
1.20 program. Mayo Clinic shall partner with the University of Minnesota to develop and oversee  
1.21 the scientific study details, testing components, and selection of participants. Mayo Clinic

2.1 and the University of Minnesota shall form an oversight committee to design the volunteer  
2.2 agreement participants must sign in order to join the pilot program.

2.3 (c) Mayo Clinic Biobank shall release the results of testing to the participant's primary  
2.4 care provider upon request of the participant and with the participant's signed release of  
2.5 information authorization.

2.6 (d) The commissioner of management and budget shall obtain information from  
2.7 participants' primary care providers after obtaining a signed release of information from  
2.8 each participant. This information will be used to determine savings in health outcomes and  
2.9 health care costs.

2.10 Subd. 3. **Report.** The commissioner of management and budget shall issue an annual  
2.11 report to the legislative committees with jurisdiction over health care. The report must  
2.12 specify the status of the program including any significant savings in health outcomes and  
2.13 lives saved and detail health care costs avoided.